drugset / Trial / NCT00165633
A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine the superiority of inhibitory effects and safety of Menatetrenone (E0167) on recurrence in patients with hepatocellular carcinoma.
Timeline
- Start
- 2004-03
- Primary completion
- —
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Menatetrenone | Unknown | 45 mg | Oral |
| Subject | Menatetrenone | Unknown | 90 mg | Oral |